Expansion of Contract Medical Device Design, Development and Manufacturing Through the Acquisition of Rev.1
First written in FY2021-Q3. 2 of 5 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025WorsenedAnnual report
「With respect to goodwill and other intangible assets related to the 4 companies 朝日サージカルロボティクス株式会社, Pathways Medical Corporation, Rev1. Engineering, Inc. and Asahi Medical Technologies, Inc., the company recognized impairment losses because, after taking into account the recent business environment and future business plans, it was no longer expected to recover its investment due to declining profitability and other factors.」
Recognized an impairment loss of ¥1,623 million on acquisition-related assets of Rev.1 Engineering due to lower expected recoverability. - FY2023AdvancedAnnual report
「In overseas markets, sales increased due to the recovery in procedure volumes and the benefit of foreign exchange movements, strong performance by existing products such as PCI guidewires and penetration catheters, particularly in the cardiovascular field, strong outsourced development transactions by the acquired consolidated subsidiary Rev.1 (US) in non-cardiovascular fields, and an increase in orders for OEM and ODM transactions from overseas medical device manufacturers.」
Outsourced development transactions by Rev.1 performed strongly, and OEM and ODM orders from overseas medical device manufacturers also increased. - FY2022-Q3AdvancedAnnual report
「The company resolved to transfer its ODM and OEM business in the medical device field to its wholly owned consolidated subsidiary フィルメック株式会社 to promote the business proactively.」
In addition to expanding outsourced design, development and manufacturing through the acquisition of Rev.1, the company resolved to transfer its medical device ODM and OEM businesses to フィルメック株式会社, establishing a more defined operating structure. - FY2021AchievedAnnual report
「At a Board of Directors meeting held on 12 April 2021, the company resolved to acquire shares in Rev.1 Engineering, Inc. and make it a subsidiary, and acquired all shares on 1 July 2021.」
Completed the acquisition of all shares in Rev.1 Engineering on 1 July 2021, establishing a structure to expand outsourced medical device design and development, as well as its OEM and ODM businesses, in the US. - FY2021-Q3First statedAnnual report
「The company entered into a basic agreement to consider acquiring 100% of the shares of Rev.1 for the purpose of expanding its OEM business in the US market.」
Entered into a basic agreement to consider acquiring 100% of Rev.1 Engineering, Inc., which undertakes the design and development of interventional medical devices in the US. In addition to design, development and prototyping, the company expects to expand its outsourced services through manufacturing by utilizing the group’s manufacturing bases. The share acquisition was scheduled for 1 July 2021, with an upfront payment of ¥2,916 million.